Integra LifeSciences Reports Q3 Revenue at Low End of Guidance Amid Ongoing Operational Disruptions
Integra LifeSciences (IART) reported third-quarter revenue of $411 million, landing at the lower end of its previously issued guidance range. The company also posted adjusted earnings per share of $0.59 and generated $96 million in operating cash flow during the period. Management noted that operational disruptions related to their Cincinnati facility are expected to persist longer than initially anticipated, with impacts extending into the second quarter of 2027. Despite these challenges, the company has provided a long-term revenue outlook for 2026, projecting between $1.634 billion and $1.654 billion.
Tickers: $IART
Topics: earnings per share operating cash flow revenue
Read the full article at Seeking Alpha
Part of the story Integra LifeSciences Reduces Full-Year Revenue Guidance Due to Plant Flooding and Market Competition (3 articles)